BlueSphere Bio to Present at the BIO CEO & Investor Conference
PITTSBURGH, PA, February 8, 2022 — BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a revolutionary TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced that David Apelian, M.D., Ph.D., MBA, chief executive officer of BlueSphere Bio, will present an in-person company overview at the […]
BlueSphere Bio to Present at the BIO CEO & Investor Conference Read More »